AstraZeneca invests a further A$100 million into its Sydney facility

13 Jul 2017

AstraZeneca is reinvesting a further A$100 million to expand its manufacturing facility in North Ryde, Sydney.

The investment, announced at a London event with AstraZeneca’s CEO Pascal Soriot and the Australian Prime Minister, Malcolm Turnbull, will create an additional 60 jobs and support production lines for innovative respiratory medicines.

The expanded facility is expected to drive exports to A$2.4 billion over the next four years. Three new production lines will each have the capacity to produce 70 million units per year of asthma medication called Pulmicort Respules. Locally produced, this medicine is exported to countries like China, where it can help treat some of its estimated 30 million asthma patients.

In a press release, Manufacturing Director of AstraZeneca Australia, Mark Morgan, says the manufacturing model is based on high-tech production that is difficult to replicate. ‘The machinery is a credit to Australian engineering excellence and its performance can be attributed to our workforce who achieve significant increases in productivity and efficiency out of the machines.’

AstraZeneca’s CEO Soriot says the company’s latest investment is an ‘example of the tremendous opportunities presented by high-tech manufacturing and productivity, creating jobs, boosting exports and ultimately making a positive impact on the Australian economy’.

The recent announcement from AstraZeneca builds on a 60-year history in Australia of bringing innovative medicines for cancer, diabetes and respiratory diseases to patients. The company has invested A$105 million in its North Ryde site over the last five years. By 2025, AstraZeneca is predicted to produce over 1 billion respules.